Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041426 · ClinicalTrials.gov registry record · Phase 2
Letermovir for CMV Prevention After Lung Transplantation
A Phase 2 study, sponsored by Fernanda P Silveira, MD, MS.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05041426 is a Phase 2 study that has completed, run by Fernanda P Silveira, MD, MS. The registered enrollment target is 15 participants.
The verdict
NCT05041426, a Phase 2 study, has completed, sponsored by Fernanda P Silveira, MD, MS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Letermovir
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05041426
The ClinicalTrials.gov registry entry for NCT05041426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fernanda P Silveira, MD, MS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Letermovir is the first listed.
NCT05041426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05041426 about?
NCT05041426 is a clinical study titled "Letermovir for CMV Prevention After Lung Transplantation". This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT05041426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-12-06. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT05041426?
The interventions under investigation include: Letermovir (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT05041426?
This trial is sponsored by Fernanda P Silveira, MD, MS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.